Canaccord lowered the firm’s price target on Exagen (XGN) to $10 from $15 and keeps a Buy rating on the shares. The firm noted they reported inline Q4 results and said its target reduction is driven by more muted ASP and gross margin expansion in the near term, as well as reduced revenue growth assumptions in the out years of our 10-year DCF.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN:
- Exagen price target lowered to $10 from $15 at KeyBanc
- Exagen price target lowered to $9 from $10 at BTIG
- Maintaining a Buy: Conservative Guidance but Solid Demand and Pipeline Support Long-Term Upside
- Exagen reports Q4 EPS (20c), consensus (19c)
- Exagen sees FY26 revenue $70M-$73M, consensus $73.84M